Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GILD |
---|---|---|
09:32 ET | 114330 | 63.17 |
09:34 ET | 12253 | 63.23 |
09:36 ET | 22897 | 63.12 |
09:38 ET | 16572 | 62.945 |
09:39 ET | 12506 | 63.0124 |
09:41 ET | 15641 | 62.97 |
09:43 ET | 20595 | 63.03 |
09:45 ET | 23570 | 62.94 |
09:48 ET | 27759 | 62.8765 |
09:50 ET | 16692 | 62.87 |
09:52 ET | 11409 | 62.94 |
09:54 ET | 20453 | 63.02 |
09:56 ET | 17108 | 63.06 |
09:57 ET | 13785 | 63.13 |
09:59 ET | 8612 | 63.17 |
10:01 ET | 12939 | 63.0544 |
10:03 ET | 29457 | 63.08 |
10:06 ET | 15203 | 63.145 |
10:08 ET | 16214 | 63.19 |
10:10 ET | 13346 | 63.27 |
10:12 ET | 17802 | 63.29 |
10:14 ET | 8456 | 63.24 |
10:15 ET | 11197 | 63.19 |
10:17 ET | 12522 | 63.18 |
10:19 ET | 11619 | 63.16 |
10:21 ET | 13314 | 63.215 |
10:24 ET | 16627 | 63.21 |
10:26 ET | 17294 | 63.21 |
10:28 ET | 14078 | 63.17 |
10:30 ET | 9339 | 63.15 |
10:32 ET | 15648 | 63.23 |
10:33 ET | 15113 | 63.25 |
10:35 ET | 12960 | 63.265 |
10:37 ET | 15625 | 63.2 |
10:39 ET | 12730 | 63.17 |
10:42 ET | 21057 | 63.24 |
10:44 ET | 17421 | 63.23 |
10:46 ET | 3853 | 63.23 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Gilead Sciences Inc | 79.1B | 19.3x | -13.08% |
Moderna Inc | 68.2B | 5.5x | --- |
Regeneron Pharmaceuticals Inc | 69.9B | 12.7x | +56.36% |
BioNTech SE | 39.1B | 3.5x | --- |
Vertex Pharmaceuticals Inc | 75.9B | 24.0x | --- |
IQVIA Holdings Inc | 44.7B | 40.7x | +59.92% |
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.1B |
---|---|
Revenue (TTM) | $27.5B |
Shares Outstanding | 1.3B |
Dividend Yield | 4.62% |
Annual Dividend Rate | 2.9200 USD |
Ex-Dividend Date | 09-14-22 |
Pay Date | 09-29-22 |
Beta | 0.36 |
EPS | $3.28 |
Book Value | $16.80 |
P/E Ratio | 19.3x |
Price/Sales (TTM) | 2.9 |
Price/Cash Flow (TTM) | 12.7x |
Operating Margin | 25.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.